Registered title, quoted from ClinicalTrials.gov
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07647263, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 9
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (9 points)Hide the checklist
18 years to Not stated; sex: women only
Registered eligibility fields
2.Pathologically confirmed invasive breast cancer, stage II-III according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system, with HER2-positive disease defined as: immunohistochemistry (IHC) 3+; or IHC 2+ with confirmed HER2 gene amplification by fluorescence in situ hybridization (FISH).
Inclusion criterion 2
8.No evidence of myocardial ischemia on electrocardiogram (ECG); New York Heart Association (NYHA) functional class I; left ventricular ejection fraction (LVEF) ≥55% on echocardiogram; cardiac biomarkers (cardiac troponin I [cTnI] and B-type natriuretic peptide [BNP]) within normal limits.
Inclusion criterion 15
2.Metastatic breast cancer (Stage IV).
Exclusion criterion 2
4.No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer.
Inclusion criterion 4
9.All required baseline laboratory and radiologic examinations completed prior to neoadjuvant therapy.
Inclusion criterion 16
6.Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipated need for major surgery during the study period.
Exclusion criterion 6
7.Receipt of radiotherapy, chemotherapy, molecular targeted therapy, endocrine therapy, or major breast surgery for breast cancer within 4 weeks prior to study treatment; current or prior use of HER2-targeted monoclonal antibodies, HER2-targeted antibody-drug conjugates (ADCs), or tyrosine kinase inhibitors (TKIs).
Exclusion criterion 7
5.Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Inclusion criterion 5
Hemoglobin ≥90 g/L
Inclusion criterion 8
Platelet count ≥100×10⁹/L
Inclusion criterion 10
Neutrophil count ≥1.5×10⁹/L
Inclusion criterion 11
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3× upper limit of normal (ULN)
Inclusion criterion 12
Total bilirubin ≤1.5×ULN
Inclusion criterion 13
Serum creatinine ≤1.5×ULN
Inclusion criterion 14
3.At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Inclusion criterion 3
1.Male breast cancer or inflammatory breast cancer.
Exclusion criterion 1
3.Presence of other concurrent malignancies or history of malignancy other than breast cancer within the past 5 years, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
Exclusion criterion 3
4.Receipt of any other concurrent anti-cancer therapy or participation in another clinical trial.
Exclusion criterion 4
1.Age ≥18 years. For premenopausal and perimenopausal patients, a negative pregnancy test is required, and the patient must agree to use effective contraception during treatment.
Inclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07647263, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1.Age ≥18 years. For premenopausal and perimenopausal patients, a negative pregnancy test is required, and the patient must agree to use effective contraception during treatment.
- 2.Pathologically confirmed invasive breast cancer, stage II-III according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system, with HER2-positive disease defined as: immunohistochemistry (IHC) 3+; or IHC 2+ with confirmed HER2 gene amplification by fluorescence in situ hybridization (FISH).
- 3.At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
- 4.No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer.
- 5.Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- 6.Ability to understand and provide written informed consent.
- 7.Adequate organ function as evidenced by the following laboratory values:
- Hemoglobin ≥90 g/L
- White blood cell count ≥3.5×10⁹/L
- Platelet count ≥100×10⁹/L
- Neutrophil count ≥1.5×10⁹/L
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3× upper limit of normal (ULN)
- Total bilirubin ≤1.5×ULN
- Serum creatinine ≤1.5×ULN
- 8.No evidence of myocardial ischemia on electrocardiogram (ECG); New York Heart Association (NYHA) functional class I; left ventricular ejection fraction (LVEF) ≥55% on echocardiogram; cardiac biomarkers (cardiac troponin I [cTnI] and B-type natriuretic peptide [BNP]) within normal limits.
- 9.All required baseline laboratory and radiologic examinations completed prior to neoadjuvant therapy.
- 10.No dysphagia.
- 11.Availability of complete clinical data.
Exclusion Criteria:
- 1.Male breast cancer or inflammatory breast cancer.
- 2.Metastatic breast cancer (Stage IV).
- 3.Presence of other concurrent malignancies or history of malignancy other than breast cancer within the past 5 years, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
- 4.Receipt of any other concurrent anti-cancer therapy or participation in another clinical trial.
- 5.Presence of severe non-malignant disease that would compromise patient compliance or place the patient at unacceptable risk.
- 6.Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipated need for major surgery during the study period.
- 7.Receipt of radiotherapy, chemotherapy, molecular targeted therapy, endocrine therapy, or major breast surgery for breast cancer within 4 weeks prior to study treatment; current or prior use of HER2-targeted monoclonal antibodies, HER2-targeted antibody-drug conjugates (ADCs), or tyrosine kinase inhibitors (TKIs).
- 8.History of hypersensitivity or contraindication to any component of the study drugs.
- 9.Poorly controlled cardiac symptoms or diseases, including: New York Heart Association (NYHA) Class II or higher heart failure; unstable angina; myocardial infarction within 1 year; clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
Dementia, intellectual disability, or any psychiatric disorder that impairs the ability to understand the informed consent form.
Quoted from ClinicalTrials.gov, NCT07647263, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07647263, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.